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Introduction: This paper describes narcolepsy with cataplexy in two monozygotic twin sisters.
Objective: To clinically illustrate the involvement of neurological, genetic and immunologic
systems in narcolepsy.
Material and methods: We performed a restropective study of these patients that were
followed in the sleep medicine ambulatory clinic of the Faculdade de Medicina de
Ribeirao Preto.
Results: These sisters are two of the few cases in the literature concordant for narcolepsy
with catalepsy and without a “positive HLA” for narcolepsy. They had a typical clinical course of
narcolepsy with cataplexy and attended all the neurophysiological diagnostic criteria for
narcolepsy.
Conclusion: In addition to known possible genetical similarity, this report stresses the role of
environmental or unknown genetical factors acting on a speciﬁc neuro-imuno-genetical
background and resulting in narcolepsy.
& 2014 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Narcolepsy is a chronic disturbance that leaves patients
incapacitated in most cases; it is characterized by an abnor-
mal sleep pattern that may include excessive daytime sleepi-
ness, sleep architecture alterations, and rapid eye movement
(REM) sleep pathological manifestations, including sleep
paralysis, hypnagogic hallucinations, sleep onset REM period
(SOREMP) and cataplexy [1]. Symptoms typically begin in
adolescence or early adulthood and may also emerge in
childhood or old age, or even after a central nervous systemep. Production and Hosti
licenses/by-nc-nd/3.0/).
m.br (L.I. Goulart).
an Association of Sleep.structural injury [2]. Epidemiologic studies show prevalence
ranging from 0.23/100,000 in Israel to 160/100,000 in Japan [3]
with 47/100,000 in Europe [4].
The development of human narcolepsy involves environ-
mental factors acting against a speciﬁc genetic background.
One of the predisposing genetic factors is located in the MHC
(Major Histocompatibility Complex) DQ region. Up to 98% (88–
98%) of all narcoleptic patients with deﬁnite cataplexy share a
speciﬁc Human Leukocyte Antigen (HLA) allele, HLA
DQB1n0602 (mostly in combination with HLA DR2), compared
with 12–38% of the general population, as evaluated inng by Elsevier B.V. This is an open access article under the CC BY-
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 6 2 – 6 4 63various ethnic groups. This homozygous presence for the
HLA DQB1n0602 allele constitutes a known genetic risk factor
for narcolepsy, but more than 99% of the population that
have this homozygous allele do not present narcolepsy [5].
Most narcoleptic patients have low levels of hypocretin in
their cerebrospinal ﬂuid [6]. Impaired hypocretin neurotrans-
mission, possibly due to an autoimmune mechanism or by a
speciﬁc lesion, has been seen as having a fundamental role in
the pathological process [7].
Thus, the evidence suggests that narcolepsy in humans
may emerge when environmental factors act through an
immunologic mechanism in a genetic background of predis-
position for the disease. Considering that a familial pattern of
narcolepsy is rare, mainly in twins, this paper brings the
history of two of the few monozigotic twins concordant
for narcolepsy and cataplexy known in the scientiﬁc litera-
ture [8,9].2. Case reports
These case reports retrospectively cover two monozygotic
twin sisters concordant for narcolepsy. They were ﬁrst
attended at the age of 17 by the sleep disorder clinic at the
Ribeirão Preto Medical School hospital (Universidade de
São Paulo), having been referred directly from a basic health
unit in a rural area of the state of São Paulo, where they grew up
together in the same home. Their life history is very similar in
terms of type and chronology of their narcolepsy symptoms. The
twins were born on June 24, 1985 in a premature cesarean
childbirth, with water broke lasting for 5 h. There was no familial
history of narcolepsy or hypersomnia.
Twin 1 (T1) had no childbirth complications and her
neurological, psychological, and motor development was
normal. At the age of 9 yo she started to have migrane and
fatigue. At the age of 16, she began to show excessive daytime
sleepiness that affected social activities, sleep paralysis
episodes, and hypnagogic hallucinations, waking up after
the ﬁrst third of the night and hearing a voice ordering her
to get up. At 17, she had the ﬁrst cataplexy episode described
as an episode of “loss of strength”, mainly in the legs, causing
falls, and triggered by emotions (generally positive ones).
Throughout initial clinical follow-up (before treatment had
begun), she frequently complained of excessive daytime
sleepiness, exhaustion, constant fatigue that could be
relieved after brief naps, learning difﬁculty, and almost daily
cataplexy episodes (Table 1). Considering this clinical picture
she performed a polysomnography with subsequent multiple
sleep latency test – MSLT (Table 2) [10,11].
Further diagnostic assessments, such as determining HLA
haplotype (A2, A26, B49, B57, DR1, DR7, DR53, DQ2 and DQ5),
were also performed, but the presence of alleles associatedTable 1 – Clinical/genetic features.
Sleepness
onset
Cataplexy
onset
REM sleep
parasomnias
N
pa
T1 16 yo 17 yo 16 yo N
T2 14 yo 17 yo No 14with genetic susceptibility to narcolepsy was not detected
(Table 1).
Twin 2 (T2), an identical twin, remained in hospital for
38 days after childbirth complications, but her further neu-
rological, psychological and motor development was normal.
She started migrane onset at 9 yo. At 14, she reported
symptoms directly related to excess sleepiness interfering
in her everyday activities. At that time, her parents noticed
sleep talk and agitated sleep. She had her ﬁrst cataplexy
episode at the same age as T1, 17 years old. She continuously
complained of excessive sleepiness, and excessive irritability.
Unlike T1, T2 did not have sleep paralysis or hypnagogic
hallucinations, nor were there complaints related to cognitive
performance (Table 1). During initial clinical follow-up (before
results of the exams) the patient frequently complained of
sleepiness during the day, excessive irritability, tiredness,
constant fatigue relieved by short naps (30 min) during day-
time, and frequent cataplexy episodes. The polysomnography
and MSLT endorsed the clinical diagnostic of narcolepsy with
cataplexy (Table 2). The determination of HLA haplotype (A2,
A26, B49, B57, DR1, DR7, DR53, DQ2 and DQ5) did not show the
presence of alleles associated with genetic susceptibility to
narcolepsy (Table 1).
Once diagnosis was made, the therapeutical approach was
based on intermittent use of methylphenidate, continuous
use of tricyclic for cataplexy and programmed naps. With the
treatment, they became less sleepy and the frequency of the
cataplexy episodes was reduced. The patients also referred
better concentration and much less sleepiness, they had
resumed normal everyday activities such as school, working
and driving with great improvement in their life quality.3. Discussion
Narcolepsy usually occurs sporadically, but may also show a
familiar pattern. Estimates of familial incidence range from
4.3% of all narcolepsy cases in Japan to 9.9% in Canada, and,
the risk of a ﬁrst-degree relative of a patient having narco-
lepsy–cataplexy is 1–2% (10–40 times higher than the pre-
valence for the general population) which suggests a genetic
etiology. Eight of the 18 monozygotic twin pairs described in
the literature were described as concordant for the narco-
lepsy diagnosis, and only three pairs were considered “posi-
tive HLA” [5,12–14]. In other words, most monozigotic twin
pairs are discordant for narcolepsy suggesting that nonge-
netic, and even possible, environmental factors can also be
involved in the pathophysiology of human narcolepsy. In the
present cases, the presence of alleles associated with a
certain kind of genetic susceptibility (HLA) to narcolepsy
was not detected. The present paper endorses the hypothesis
of the possible involvement of other genes (besides HLA) suchREM sleep
rasomnia
Fatigue/migrane
onset
HLA (DR2/
DQB1n0602)
o 9 yo No
yo 9 yo No
Table 2 – Neurophysiologic diagnostic.
Polysomnography MSLT
Total sleep time
(min)
Sleep efﬁciency
(%)
Sleep latency
(min)
REM sleep latency
(min)
%
REM
Mean sleep latency
(min)
SOREMP
T1 432.0 91.1 25.5 63.5 32.9 5.0 2
T2 420.0 94.7 6.5 68.0 20.0 2.2 5
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 6 2 – 6 464as T-cell receptor alpha (TCRA) locus [15] as well as also
possible neuro-imuno-genetical interactions with a restricted
harmful process involving the neurons controlling hypocretin
neurotransmission [16]. Unfortunately, after 2004, the
patients described above, could not be found for further
evaluations (such as cerebrospinal ﬂuid hypocretin-1 testing).Acknowledgments
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